HealthCare Royalty (“HCRx”), Blue Owl Capital acquires BEYONTTRA's drug royalties (owned by BridgeBio)
for $300m

BridgeBio's monetization of a portion of its European royalties on BEYONTTRA through a $300 million transaction with HealthCare Royalty and Blue Owl Capital strengthens its balance sheet to support the launch of Attruby® and its late-stage pipeline programs. By selling 60% of anticipated royalties from the first $500 million in annual net sales, BridgeBio secures immediate capital without diluting equity, subject to a cap of 1.45x total payments. This structuring limits both annual and cumulative payouts to investors while preserving potential upside for shareholders. The deal shifts competitive dynamics by positioning BridgeBio with additional financial resources to accelerate commercialization efforts and pipeline development. Competitors may now face strategic pressures to secure similar financing or risk falling behind in the race to launch innovative therapies. The transaction also underscores HCRx and Blue Owl's confidence in BEYONTTRA’s commercial prospects, potentially attracting further investment interest. Post-closure risks include regulatory challenges that could delay or restrict BEYONTTRA's market access, impacting royalty payments. Integration challenges are minimal given the monetization structure rather than a direct acquisition, but BridgeBio must monitor sales performance closely to ensure it meets the capped payment thresholds without forfeiting potential revenue. Growth vectors post-close will hinge on successful commercial launches and pipeline advancements, bolstered by the enhanced financial stability from this transaction.